

The Pharma Jukebox

VOLUME 1, ISSUE 7 | OCTOBER 2011 NEWSLETTER

"Make daily work and processes easy to Understand & Simple to execute"

-Vishal Jajodia
CEO

From the editor's desk:

Team Anna v/s Team Sibal, whom did you support? The whole Jan Lokpal Bill gathered enormous 'undeserved' attention. Whether or not corruption will be wiped out from our country, is the question most of us are interested in!

However, the world is trapped by a number of uncertain questions as to whether the Pharma companies will sustain the "pressure" for developing drugs for neglected diseases. To unshackle these, many pharma companies are working with non-profit organizations to share R&D results in a bid to improve efficiency.

GSK, Bayer and Novartis are TB alliance partners, Lupin is involved in the TB alliance project and is in partnership with CSIR. Even Sanofi-Aventis is in partnership with DNDI and introduced a successful anti-malarial drug for less than \$1 in Africa.

This issue of "The Pharma Jukebox" brings you the other side of the industry and the efforts taken by pharma companies to strengthen the commitment to work on neglected diseases.

Sanaa Jummal
Editor

Feedback At:

Email: pr@spentose.com

Contact Details:
+91- 22- 6150 5226

"I would prefer even to fail with honor than to win by cheating"
-Sophocles

The Jan Lokpal Bill received an overwhelming response to fight against the corrupt politicians. But sooner or later the shutter-bugs will redirect themselves from "corrupt politicians" to "dishonest corporate".

Every coin has two sides. Contrary to its 'bad' image, the industry also has some good deeds for itself. Whether knowingly or unknowingly, the pharma companies control many facets of our lives.

The pharmaceutical majors are quite involved in developing drugs for neglected diseases. The business-model however is not profit oriented but instead depends on highly subsidized R&D and hence only a few pharmaceutical companies are currently devoting their R&D to find solutions for neglected



diseases.

Sanofi and DNDI (Drugs for Neglected Disease Initiative) announced on May 30, 2011, a three year collaboration for the treatment of nine neglected diseases listed by

the WHO.

Swati Spentose Pvt Ltd (SSPL) has dedicated years long research in the development of medicines to fight diseases such as Interstitial Cystitis, Varicose Veins etc among many others.

Patients using Varicogel have reported being cured of Varicose Veins. A patient suffering from Interstitial Cystitis testified being relieved of the intense pain.

For further details visit us at:

www.spentose.com
www.comfora.in
www.comforachemist.in

We hope that the pharma companies continue to play leading roles in eradicating neglected diseases in the near future.

I'd like to hear from you. Do write back to me at pr@spentose.com

Swati Spentose Pvt. Ltd

- ➔ Swati Spentose Pvt Ltd, is a subsidiary of the 40 year old Euresian group.
- ➔ Swati Spentose has established unique-cutting edge technology platforms in the development of Polysaccharides bio-generics, in collaboration with world renowned research platforms like Mt Sinai School of Medicine and clinicians and scientists world over.
- ➔ The key therapeutic areas of Swati Spentose include urology, chronic progressive vascular disease and diabetes among others.

Our Basket of Finished Dosages:



Dutride T



Dutride



Comfora



Terod



FinFlow

We offer following API's from USFDA, EDQM, UKMCA, TGA Australia, MCC-South Africa approvable site :

- Pentosan Polysulfate sodium
- Dextran Salts
- Hydroxyl Ethyl Starch
- Lidocaine HCl / Base
- Meloxicam
- Phenytoin Base / Sodium

For further information contact : api@spentose.com



SWATI SPENTOSE PVT. LTD.

114, Marine Chambers,
11, New Marine Lines,
Mumbai-400 020, India.
Tel-0091-22-66332427
Fax-0091-22-22071955

For more information visit us at : www.spentose.com

Or Drop in a mail at pr@spentose.com

Or Give us a call at the number mentioned to the left